EcoDrugPlus

Protein Kinase C, Beta A

Ensembl ID : ENSOSIG00000013284
Gene Symbol: PRKCBA
1 Cross references
223 Possible Orthologues:

Protein Kinase C, Eta, A

Ensembl ID : ENSOSIG00000007837
Gene Symbol: PRKCHA
1 Cross references
224 Possible Orthologues:

Protein Kinase C, Zeta

Ensembl ID : ENSOSIG00000015178
Gene Symbol: PRKCZ
1 Cross references
201 Possible Orthologues:

Protein Kinase D1

Ensembl ID : ENSOSIG00000012200
Gene Symbol: PRKD1
1 Cross references
204 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSOSIG00000001625
Gene Symbol: PRKD3
1 Cross references
201 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSOSIG00000001129
Gene Symbol: PRKD3
1 Cross references
209 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSOSIG00000017111
Gene Symbol: PPP3CA
1 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta, B

Ensembl ID : ENSOSIG00000021680
Gene Symbol: PTK2BB
1 Cross references
195 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11a

Ensembl ID : ENSOSIG00000019311
Gene Symbol: PTPN11A
1 Cross references
251 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSOSIG00000003078
Gene Symbol: PTPRB
1 Cross references
203 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSOSIG00000019769
Gene Symbol: PTPRB
1 Cross references
189 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSOSIG00000015087
Gene Symbol: P2RX3A
1 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).